143 related articles for article (PubMed ID: 34354010)
1. Changing Patterns of Lymphoma in the Antiretroviral Therapy Era in Johannesburg, South Africa.
Wiggill T; Mayne E; Perner Y; Vaughan J
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):252-260. PubMed ID: 34354010
[TBL] [Abstract][Full Text] [Related]
2. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective.
Wiggill TM; Mantina H; Willem P; Perner Y; Stevens WS
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):460-6. PubMed ID: 21239997
[TBL] [Abstract][Full Text] [Related]
3. Diffuse Large B-Cell Lymphoma in the Public-Sector of Johannesburg, South Africa, in the Era of Widescale Antiretroviral Therapy Use.
Vaughan J; Perner Y; Wiggill T
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):335-342. PubMed ID: 35916644
[TBL] [Abstract][Full Text] [Related]
4. Head and neck lymphomas: A 20-year review in an Oral Pathology Unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS.
Alli N; Meer S
Oral Oncol; 2017 Apr; 67():17-23. PubMed ID: 28351573
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: HIV-Associated Hodgkin Lymphoma Involving the Bone Marrow Identifies a Very High-Risk Subpopulation in the Era of Widescale Antiretroviral Therapy Use in Johannesburg, South Africa.
Vaughan J; Perner Y; McAlpine E; Wiggill T
J Acquir Immune Defic Syndr; 2020 Apr; 83(4):345-349. PubMed ID: 32097194
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and spectrum of head and neck lymphomas at Tygerberg Hospital, South Africa, 2003 to 2007.
Chetty M; Sudi S; Abayomi EA
SADJ; 2012 Jul; 67(6):270, 272-4, 276-7. PubMed ID: 23185941
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use.
Vaughan J; Perner Y; Mayne E; Wiggill T
HIV Med; 2021 Mar; 22(3):225-230. PubMed ID: 33022825
[TBL] [Abstract][Full Text] [Related]
8. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes of HIV positive patients with lymphoma in an oncological reference center in Mexico City.
Cardenas-Ortega A; Ramírez-Ibarguen AF; Rivera-Buendía F; Pérez-Jiménez C; Volkow-Fernández P; Martin-Onraet A
Medicine (Baltimore); 2020 Oct; 99(40):e22408. PubMed ID: 33019417
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.
Hoffmann C; Hentrich M; Gillor D; Behrens G; Jensen B; Stoehr A; Esser S; van Lunzen J; Krznaric I; Müller M; Oette M; Hensel M; Thoden J; Fätkenheuer G; Wyen C
HIV Med; 2015 Apr; 16(4):261-4. PubMed ID: 25252101
[TBL] [Abstract][Full Text] [Related]
11. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.
Gopal S; Patel MR; Yanik EL; Cole SR; Achenbach CJ; Napravnik S; Burkholder GA; Reid EG; Rodriguez B; Deeks SG; Mayer KH; Moore RD; Kitahata MM; Eron JJ; Richards KL
J Natl Cancer Inst; 2013 Aug; 105(16):1221-9. PubMed ID: 23892362
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Lymphomas in a high prevalence HIV setting.
Mantina H; Wiggill TM; Carmona S; Perner Y; Stevens WS
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):656-60. PubMed ID: 20160652
[TBL] [Abstract][Full Text] [Related]
13. Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
Fontas E; Kousignian I; Pradier C; Duvivier C; Poizot-Martin I; Durier C; Jarrousse B; Weiss L; Levy Y; Costagliola D;
J Acquir Immune Defic Syndr; 2009 Feb; 50(2):206-14. PubMed ID: 19131886
[TBL] [Abstract][Full Text] [Related]
14. Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART).
Chow KU; Mitrou PS; Geduldig K; Helm EB; Hoelzer D; Brodt HR
Leuk Lymphoma; 2001 Mar; 41(1-2):105-16. PubMed ID: 11342362
[TBL] [Abstract][Full Text] [Related]
15. Malignant lymphomas (ML) and HIV infection in Tanzania.
Mwakigonja AR; Kaaya EE; Mgaya EM
J Exp Clin Cancer Res; 2008 Jun; 27(1):9. PubMed ID: 18577266
[TBL] [Abstract][Full Text] [Related]
16. Incidence, Treatment, and Outcome of HIV-Associated Hematologic Malignancies in People Living with HIV in Sweden.
Kieri O; Marrone G; Sönnerborg A; Nowak P
AIDS Res Hum Retroviruses; 2022 Feb; 38(2):135-142. PubMed ID: 34652958
[TBL] [Abstract][Full Text] [Related]
17. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study.
D'Addario G; Dieterle A; Torhorst J; Maibach R; Stahel R; Egli F; Lohri A; Cavalli F; Fey M; Ketterer N; Cerny T
Leuk Lymphoma; 2003 Jan; 44(1):133-8. PubMed ID: 12691153
[TBL] [Abstract][Full Text] [Related]
18. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.
Shepherd L; Ryom L; Law M; Hatleberg CI; de Wit S; Monforte AD; Battegay M; Phillips A; Bonnet F; Reiss P; Pradier C; Grulich A; Sabin C; Lundgren J; Mocroft A
J Natl Cancer Inst; 2018 Jun; 110(6):598-607. PubMed ID: 29267895
[TBL] [Abstract][Full Text] [Related]
19. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
[TBL] [Abstract][Full Text] [Related]
20. Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification.
Sukpanichnant S
Hum Pathol; 2004 Feb; 35(2):224-30. PubMed ID: 14991541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
